Journal of Nanomedicine & Nanotechnology

Combined therapeutic efficacy of 188Re-liposome and capecitabine in an experimental colorectal cancer liver metastases model by intrasplenic injection of the C26-luc murine colon cancer cell line

4^th International Conference on Nanotek & Expo

December 01-03, 2014 DoubleTree by Hilton Hotel San Francisco Airport, USA

Ya-Jen Chang

Posters: J Nanomed Nanotechnol

Abstract:

188Re displays abundant intermediate energy β emission, and possesses an appropriate physical half-life of 16.9 hours. Liposomes are good drug delivery system, which allow the encapsulation of drugs into vesicles for their delivery. Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of numerous cancers such as breast cancer and colorectal cancers. Capecitabine (Xeloda?) is a prodrug, that is enzymatically converted to 5-fluorouracil. It was investigated the efficacy of the radiotherapeutics of 188Re-liposome combined with capecitabine in a C26-luc metastatic colorectal liver tumors mice model. Liver metastases were established by intrasplenic injection of C26-luc murine colon cancer cells. 188Reliposome was given at day 1. In the combination therapy group, 359 mg/kg capecitabine was administered every day for five days, and the tumor growth and survival rates of the treated mice were examined. Bioluminescence images were taken using an IVIS Spectrumto monitor tumor growth. Tumor growth inhibition from 188Re-liposome with capecitabin was superior to 188Re-liposome alone, capecitabin alone, and the untreated normal saline groups. Further, the tumor-bearing mice treated with 188Re-liposome combined with capecitabine showed longer median survival time and better life span (47.75 d; 229%) than those treated with 188Re-liposome alone(40.50 d; 179%), capecitabin alone (21.25 d; 47%) , and the untreated normal saline groups (14.50 d). These results support the possible use of combined radiochemotherapy of 188Re-liposome with capecitabin as a viable treatment option in an adjuvant setting for colorectal cancer liver metastases.

Biography :

Ya-Jen Chang has completed her master degree at the age of 24 years from National Chiao Tung University of Institute of Biochemical Engineering, Taiwan. She is Assistant Engineer (2004-until now) of Institute of Nuclear Energy Research, Taiwan. The aim of works was to investigate the drugs for cancer therapy. She has published more than 17 papers on nanomedicine and nuclear medicine journals.